Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
We compared the efficacy of combination posaconazole-liposomal amphotericin B (LAmB) therapy to monotherapy with either drug in diabetic ketoacidotic or neutropenic mice with disseminated zygomycosis caused by Rhizopus oryzae. Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo.
Ibrahim
Ashraf S
AS
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, 90502, USA. ibrahim@labiomed.org
Gebremariam
Teclegiorgis
T
Schwartz
Julie A
JA
Edwards
John E
JE
Spellberg
Brad
B
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology / Q000473:pathology; D016883:Diabetic Ketoacidosis / Q000150:complications; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D007668:Kidney / Q000382:microbiology / Q000473:pathology; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009503:Neutropenia / Q000150:complications; D012233:Rhizopus; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D020096:Zygomycosis / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D004338:Drug Combinations; D008081:Liposomes; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B